Article
Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction.
American journal of physiology. Heart and circulatory physiology - 1 Feb 2007
Baber Syed R, Deng Weiwen, Master Ryan G, Bunnell Bruce A, Taylor Bradley K, Murthy Subramanyam N, Hyman Albert L, Kadowitz Philip J
Abstract excerpt
The administration of mesenchymal stem cells (MSCs) has been proposed for the treatment of pulmonary hypertension. However, the effect of intratracheally administered MSCs on the pulmonary vascular bed in monocrotaline-treated rats has not been determined. In the present study, the effect of intr...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.